Nurse Practitioner Program year 2024 Reported 2022–2024 Source: CMS Open Payments, 2026 publication

Jessica Mariani

Neurology Cooper City, FL Nurse Practitioner

NPI 1407571458 CMS profile 11417637

5726 Sw 89Th Way, Cooper City, FL 33328

Open in the dashboard

General payments

$3,172

65 records reported · program years 2022–2024

Research payments

$0

Paid to them · None reported · program years 2022–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jessica Mariani of Cooper City, FL is reported in the CMS Open Payments database as having received $3,172 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $308 15
2023 General $2,747 49
2022 General $117 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Mariani
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jessica Mariani were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jessica Mariani Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $117 $442 $103–$2,388 $149
2023 $2,747 $464 $119–$2,312 $160
2024 $308 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2022–2024
  1. AstraZeneca Pharmaceuticals LP $1,716 15 payments
  2. AbbVie, Inc. $554 22 payments
  3. Amgen Inc. $224 9 payments
  4. Janssen Biotech, Inc. $205 4 payments
  5. Novartis Pharmaceuticals Corporation $106 3 payments
  6. GlaxoSmithKline, LLC. $82 1 payment
  7. Otsuka America Pharmaceutical, Inc. $69 1 payment
  8. UCB, Inc. $60 3 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $47 2 payments
  10. Mallinckrodt Hospital Products Inc. $31 2 payments
  11. Other $78 3 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2024
  1. Food and Beverage $1,817 59 payments
  2. Travel and Lodging $1,355 6 payments
Products named General payments · program years 2022–2024
  1. SAPHNELO $1,716 15 payments
  2. RINVOQ $311 19 payments
  3. TREMFYA $205 4 payments
  4. Otezla $141 5 payments
  5. SKYRIZI $126 2 payments
  6. UBRELVY $117 1 payment
  7. ILARIS $106 3 payments
  8. BENLYSTA $82 1 payment
  9. HUMIRA $72 11 payments
  10. REXULTI $69 1 payment
  11. Other $360 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record